Alignment Healthcare, the Healthcare sector company, was revisited by a Wall Street analyst on September 9. Analyst Kevin Fischbeck from Bank of America Securities reiterated a Buy rating on the stock and has a $23.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kevin Fischbeck has given his Buy rating due to a combination of factors that highlight Alignment Healthcare’s strong performance and potential for future growth. One of the key reasons is that Alignment Healthcare has achieved a significant milestone by ensuring that 100% of its Medicare Advantage members are enrolled in 4-star plans for the plan year 2026, which aligns with their current enrollment status. This achievement is particularly notable given that the company just surpassed the 4-star threshold for the 2025 plan year, benefiting from a favorable change in the calculation of star ratings.
Such a strong position in star ratings is crucial as it reflects the quality and performance of the healthcare services provided by Alignment Healthcare. The stability in maintaining high star ratings suggests a positive outlook for the company’s earnings and growth potential. As a result, Fischbeck’s Buy rating reflects confidence in Alignment Healthcare’s ability to sustain its high standards and capitalize on the favorable conditions in the Medicare Advantage market.
Fischbeck covers the Healthcare sector, focusing on stocks such as UnitedHealth, Centene, and Humana. According to TipRanks, Fischbeck has an average return of 3.2% and a 59.21% success rate on recommended stocks.
In another report released on September 9, Leerink Partners also maintained a Buy rating on the stock with a $20.00 price target.